We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Cutting-Edge Diagnostic Products and Solutions

By LabMedica International staff writers
Posted on 23 Jul 2023

Randox Laboratories (Crumlin, UK) is exhibiting its cutting-edge diagnostic products and solutions at 2023 AACC, while also highlighting its groundbreaking technologies. More...

As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including quality control, molecular diagnostics, third-party reagents, point of care, and clinical chemistry analyzers. With an extensive product range offering expansive third-party quality controls and calibrators, inter-laboratory data management, external quality assessments, and calibration verification. Randox’s new Acusera Quality Controls for 2022/2023 highlighted at the show include Active B12, Anti Mullerian Hormone (AMH), Brain Natriuretic Peptide (BNP) Control, Bone Markers (Serum) Control, Pre-eclampsia Control, Serum Indices Control, Ultra-Low PSA Control, Xanthochromia Control.

At AACC 2023, Randox is also showcasing its recently launched and the world’s first Xylazine ELISA. Xylazine, which is an analgesic drug primarily used within the veterinary industry as a tranquilizer, has not been approved for human use but has been linked to the USA’s illicit drug supply in recent years. While the prevalence of Xylazine is showing no sign of decreasing, Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market. The company’s newly-established test for xylazine is the first immunoassay test in the world for this drug of abuse and is available on the Evidence MultiSTAT analyzer. Evidence MultiSTAT is designed to work across a variety of matrices including blood, and oral fluid, and simultaneously screens for up to 29 drugs of abuse from a single sample in less than 31 minutes.

In recent years, Randox has been expanding its Randox Health testing – bringing preventative healthcare directly to the public. Specializing in ‘Pre-disease’ highly sensitive biomarkers in the blood are measured before an individual start to feel sick and before regular blood tests would show illness. After making the service available throughout the UK and Ireland via its innovative mobile health clinic, Randox is now unveiling Randox Health Labs located in Santa Monica, California at AACC 2023. Randox’s extensive test menu offers over 150 analytes, allowing access some of the most specialized tests available in the market today.

Related Links:
Randox Laboratories 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.